X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The drugs include Mounjaro, also known as tirzepatide, and semaglutide, which is sold under the brand names Wegovy, Ozempic ...

Two drugs targeting lipoprotein(a ... Other key studies included intensive blood pressure management in type 2 diabetes, as ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound ... effects as this is a new trend ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...